Nanocarrier system Agents Indication Status Reference RGDfK-G3 Poly-lysine dendrimer Doxorubicin + siRNA Glioblastoma Preclinical [178] Dendritic PEG Paclitaxel + Alendronate Cancer bone metastases Preclinical [233] Folate-G5 poly-propyleneimine dendrimer with ethylenediamine core Methotrexate + all-trans-retinoic acid Leukemia Preclinical [233] G5 PAMAM dendrimer Antisense-miRNA21 + 5-Fluorouracil Glioblastoma Preclinical [234] Aptamer-G4 PAMAM dendrimer conjugates Unmethylated CpG-ONTs + Doxorubicin Prostate Preclinical [235] PLGA Vincristine + Verapamil Hepatocellular carcinoma Preclinical [236] Methoxy PEG-PLGA Doxorubicin + Paclitaxel Various cancer Preclinical [237] PLGA-PEG-biotin Paclitaxel + Tariquidar Various cancer Preclinical [238] PLGA-PEG-biotin Paclitaxel + P-gp siRNA Various cancer Preclinical [239] HPMA-Gem-Dox Gemcitabine +Doxorubicin Prostate cancer Preclinical [240] HER2 conjugated- GMO-MNPs Paclitaxel + Rapamycin Breast cancer Preclinical [241]  Ac-(AF)6-H5-K15-NH2 (FA32) micelle Doxorubicin+p53 gene Hepatocarcinoma Preclinical [212] Abbrviations: RGD: Arginylglycylaspartic acid; siRNA: Small interfering ribonucleic acid; miRNA: Micro ribonucleic acid; HER2: Human Epidermal Growth Factor Receptor 2; PEG: Polyethylene glycol; PLGA: Poly(lactic-co-glycolic acid); PAMAM: Polyamidoamine; HPMA: Poly(N-(2-hydroxypropyl)methacrylamide); MNP: Magnetic nanoparticles.

Table 4: Nanoparticles based combination therapy.